Guidelines for diagnosis and treatment in Japan

Yuukou Kitagawa, Hiroyuki Kuwano

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Guidelines for diagnosis and treatment of carcinoma of the esophagus were developed to provide recommendations concerning standard treatments for carcinoma of the esophagus, facilitating the daily clinical practice of esophageal carcinoma management (The Japan Esophageal Society, Guidelines for diagnosis and treatments of esophageal cancer, Kanehara Co. Ltd.: Tokyo, 2012). The third edition of guidelines was published in 2012, covering not only therapeutic issues but also diagnostic aspects. English version of the 3rd edition of guidelines is now under preparation. This chapter was described by summarized and modified the contents of draft version of the 3rd edition of guidelines. Comprehensive evaluation of clinical stage and general condition of the patients are critically important because therapeutic strategies are often greatly influenced by patient-specific factors. There is a significant difference of common histological types of esophageal carcinoma between the East and the West. Therefore, Japanese oncologists could not directly introduce guidelines recommended by western countries based on evidence from clinical studies including adenocarcinoma with different clinicopathological factors. Although multimodal treatment is now mainstay as a therapeutic strategy for esophageal carcinoma in the whole world, a role and survival impact of surgical treatment among multimodal approach is more obvious and significant in Japan. In the 2012 edition of guidelines, preoperative neoadjuvant chemotherapy with cisplatin and 5-FU is recommended as a standard treatment for resectable stage II or III thoracic esophageal carcinoma (2002 UICC classification) based on the results of randomized controlled trial (RCT) conducted by Japan Clinical Oncology Group (JCOG) which is the largest and the most reliable cooperative study group in Japan. On the other hand, neoadjuvant chemoradiation is the standard approach in the West. As summarized in this chapter, the 2012 edition of guidelines has covered wide range of clinical issues in the management of esophageal carcinoma comprehensively. Utilizing accumulated knowledge in the 2012 edition, we should pay attention to make more clear and concise message for users of the guidelines in the future.

Original languageEnglish
Title of host publicationEsophageal Squamous Cell Carcinoma: Diagnosis and Treatment
PublisherSpringer Japan
Pages115-136
Number of pages22
ISBN (Print)9784431549772, 9784431549765
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Japan
Guidelines
Carcinoma
Combined Modality Therapy
Therapeutics
Esophagus
Medical Oncology
Tokyo
Esophageal Neoplasms
Fluorouracil
Cisplatin
Adenocarcinoma
Thorax
Randomized Controlled Trials
Drug Therapy
Survival

Keywords

  • Algorithm for treatment strategies
  • Barrett’s carcinoma
  • Double carcinoma
  • Esophagogastric junction
  • Guidelines for diagnosis and treatment
  • Palliative care
  • Salvage surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kitagawa, Y., & Kuwano, H. (2015). Guidelines for diagnosis and treatment in Japan. In Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment (pp. 115-136). Springer Japan. https://doi.org/10.1007/978-4-431-54977-2_7

Guidelines for diagnosis and treatment in Japan. / Kitagawa, Yuukou; Kuwano, Hiroyuki.

Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment. Springer Japan, 2015. p. 115-136.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kitagawa, Y & Kuwano, H 2015, Guidelines for diagnosis and treatment in Japan. in Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment. Springer Japan, pp. 115-136. https://doi.org/10.1007/978-4-431-54977-2_7
Kitagawa Y, Kuwano H. Guidelines for diagnosis and treatment in Japan. In Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment. Springer Japan. 2015. p. 115-136 https://doi.org/10.1007/978-4-431-54977-2_7
Kitagawa, Yuukou ; Kuwano, Hiroyuki. / Guidelines for diagnosis and treatment in Japan. Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment. Springer Japan, 2015. pp. 115-136
@inbook{3651d571b3294f45815619d66233cf6b,
title = "Guidelines for diagnosis and treatment in Japan",
abstract = "Guidelines for diagnosis and treatment of carcinoma of the esophagus were developed to provide recommendations concerning standard treatments for carcinoma of the esophagus, facilitating the daily clinical practice of esophageal carcinoma management (The Japan Esophageal Society, Guidelines for diagnosis and treatments of esophageal cancer, Kanehara Co. Ltd.: Tokyo, 2012). The third edition of guidelines was published in 2012, covering not only therapeutic issues but also diagnostic aspects. English version of the 3rd edition of guidelines is now under preparation. This chapter was described by summarized and modified the contents of draft version of the 3rd edition of guidelines. Comprehensive evaluation of clinical stage and general condition of the patients are critically important because therapeutic strategies are often greatly influenced by patient-specific factors. There is a significant difference of common histological types of esophageal carcinoma between the East and the West. Therefore, Japanese oncologists could not directly introduce guidelines recommended by western countries based on evidence from clinical studies including adenocarcinoma with different clinicopathological factors. Although multimodal treatment is now mainstay as a therapeutic strategy for esophageal carcinoma in the whole world, a role and survival impact of surgical treatment among multimodal approach is more obvious and significant in Japan. In the 2012 edition of guidelines, preoperative neoadjuvant chemotherapy with cisplatin and 5-FU is recommended as a standard treatment for resectable stage II or III thoracic esophageal carcinoma (2002 UICC classification) based on the results of randomized controlled trial (RCT) conducted by Japan Clinical Oncology Group (JCOG) which is the largest and the most reliable cooperative study group in Japan. On the other hand, neoadjuvant chemoradiation is the standard approach in the West. As summarized in this chapter, the 2012 edition of guidelines has covered wide range of clinical issues in the management of esophageal carcinoma comprehensively. Utilizing accumulated knowledge in the 2012 edition, we should pay attention to make more clear and concise message for users of the guidelines in the future.",
keywords = "Algorithm for treatment strategies, Barrett’s carcinoma, Double carcinoma, Esophagogastric junction, Guidelines for diagnosis and treatment, Palliative care, Salvage surgery",
author = "Yuukou Kitagawa and Hiroyuki Kuwano",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-4-431-54977-2_7",
language = "English",
isbn = "9784431549772",
pages = "115--136",
booktitle = "Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Guidelines for diagnosis and treatment in Japan

AU - Kitagawa, Yuukou

AU - Kuwano, Hiroyuki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Guidelines for diagnosis and treatment of carcinoma of the esophagus were developed to provide recommendations concerning standard treatments for carcinoma of the esophagus, facilitating the daily clinical practice of esophageal carcinoma management (The Japan Esophageal Society, Guidelines for diagnosis and treatments of esophageal cancer, Kanehara Co. Ltd.: Tokyo, 2012). The third edition of guidelines was published in 2012, covering not only therapeutic issues but also diagnostic aspects. English version of the 3rd edition of guidelines is now under preparation. This chapter was described by summarized and modified the contents of draft version of the 3rd edition of guidelines. Comprehensive evaluation of clinical stage and general condition of the patients are critically important because therapeutic strategies are often greatly influenced by patient-specific factors. There is a significant difference of common histological types of esophageal carcinoma between the East and the West. Therefore, Japanese oncologists could not directly introduce guidelines recommended by western countries based on evidence from clinical studies including adenocarcinoma with different clinicopathological factors. Although multimodal treatment is now mainstay as a therapeutic strategy for esophageal carcinoma in the whole world, a role and survival impact of surgical treatment among multimodal approach is more obvious and significant in Japan. In the 2012 edition of guidelines, preoperative neoadjuvant chemotherapy with cisplatin and 5-FU is recommended as a standard treatment for resectable stage II or III thoracic esophageal carcinoma (2002 UICC classification) based on the results of randomized controlled trial (RCT) conducted by Japan Clinical Oncology Group (JCOG) which is the largest and the most reliable cooperative study group in Japan. On the other hand, neoadjuvant chemoradiation is the standard approach in the West. As summarized in this chapter, the 2012 edition of guidelines has covered wide range of clinical issues in the management of esophageal carcinoma comprehensively. Utilizing accumulated knowledge in the 2012 edition, we should pay attention to make more clear and concise message for users of the guidelines in the future.

AB - Guidelines for diagnosis and treatment of carcinoma of the esophagus were developed to provide recommendations concerning standard treatments for carcinoma of the esophagus, facilitating the daily clinical practice of esophageal carcinoma management (The Japan Esophageal Society, Guidelines for diagnosis and treatments of esophageal cancer, Kanehara Co. Ltd.: Tokyo, 2012). The third edition of guidelines was published in 2012, covering not only therapeutic issues but also diagnostic aspects. English version of the 3rd edition of guidelines is now under preparation. This chapter was described by summarized and modified the contents of draft version of the 3rd edition of guidelines. Comprehensive evaluation of clinical stage and general condition of the patients are critically important because therapeutic strategies are often greatly influenced by patient-specific factors. There is a significant difference of common histological types of esophageal carcinoma between the East and the West. Therefore, Japanese oncologists could not directly introduce guidelines recommended by western countries based on evidence from clinical studies including adenocarcinoma with different clinicopathological factors. Although multimodal treatment is now mainstay as a therapeutic strategy for esophageal carcinoma in the whole world, a role and survival impact of surgical treatment among multimodal approach is more obvious and significant in Japan. In the 2012 edition of guidelines, preoperative neoadjuvant chemotherapy with cisplatin and 5-FU is recommended as a standard treatment for resectable stage II or III thoracic esophageal carcinoma (2002 UICC classification) based on the results of randomized controlled trial (RCT) conducted by Japan Clinical Oncology Group (JCOG) which is the largest and the most reliable cooperative study group in Japan. On the other hand, neoadjuvant chemoradiation is the standard approach in the West. As summarized in this chapter, the 2012 edition of guidelines has covered wide range of clinical issues in the management of esophageal carcinoma comprehensively. Utilizing accumulated knowledge in the 2012 edition, we should pay attention to make more clear and concise message for users of the guidelines in the future.

KW - Algorithm for treatment strategies

KW - Barrett’s carcinoma

KW - Double carcinoma

KW - Esophagogastric junction

KW - Guidelines for diagnosis and treatment

KW - Palliative care

KW - Salvage surgery

UR - http://www.scopus.com/inward/record.url?scp=84943381494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943381494&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54977-2_7

DO - 10.1007/978-4-431-54977-2_7

M3 - Chapter

AN - SCOPUS:84943381494

SN - 9784431549772

SN - 9784431549765

SP - 115

EP - 136

BT - Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment

PB - Springer Japan

ER -